bexarotene has been researched along with Intestinal Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bommi, PV; Borras, E; Bowen, CM; Chang, K; Lynch, PM; Ozcan, Z; Reyes-Uribe, L; Scheet, PA; Sinha, KM; Taggart, MW; Thirumurthi, S; Vilar, E; Walter, L; Wu, W | 1 |
| Chang, WC; Clapper, ML; Fischer, SM; Grubbs, CJ; Juliana, MM; Lubet, RA; McCormick, DL; Pereira, MA; Steele, VE | 1 |
| Choi, CI; Janakiram, NB; Mohammed, A; Qian, L; Rao, CV; Steele, VE | 1 |
3 other study(ies) available for bexarotene and Intestinal Neoplasms
| Article | Year |
|---|---|
Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
Topics: Adenomatous Polyposis Coli; Adenomatous Polyps; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinogenesis; Case-Control Studies; Cells, Cultured; Female; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Intestinal Neoplasms; Male; Mice; Mice, Transgenic; Sulindac | 2021 |
Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Bexarotene; Celecoxib; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Female; Head and Neck Neoplasms; Intestinal Neoplasms; Male; Mammary Neoplasms, Animal; Mice; Mice, Knockout; Neoplasms; Pyrazoles; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Sulfonamides; Tetrahydronaphthalenes; Urinary Bladder Neoplasms | 2012 |
Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apc(Min/+) mice.
Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Animals; Anticarcinogenic Agents; Bexarotene; Cell Proliferation; Cell Transformation, Neoplastic; Cyclin D1; Cyclooxygenase 2; Cytokines; Drug Screening Assays, Antitumor; Female; Intestinal Mucosa; Intestinal Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Inbred C57BL; Oleic Acid; Retinoid X Receptor alpha; Tetrahydronaphthalenes; Triglycerides | 2012 |